Cannabis Law Report
SEPTEMBER 13, 2021
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. Media: media@mymd.com. in the blood. 646) 421-9523.
The Cannigma
MAY 19, 2021
This was notoriously reflected in the 2020 arrest of a Japanese man and woman for speaking positively about using cannabis in social media posts. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
OCTOBER 5, 2021
The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. Media: media@mymd.com. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. Investor: Robert Schatz. 646) 421-9523.
Cannabis Law Report
AUGUST 21, 2019
The watchdog refused to allow its national health service to prescribe medical cannabis for children with severe epilepsy because there is “not enough evidence it works”, a decision which angered campaigners and parents who said their children will suffer as a result. The final guideline is expected to be published in November 2019.
Cannabis Law Report
SEPTEMBER 22, 2021
Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Media Contact: media@mymd.com. About MyMD Pharmaceuticals, Inc. 646) 421-9523.
Cannabis Law Report
SEPTEMBER 24, 2019
T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.
MMJ Recs
DECEMBER 22, 2023
Studies have shown the efficacy of medical cannabis in treating conditions such as chronic pain, epilepsy, and certain mental health disorders. Media Portrayal and Its Role in Shaping Medical Cannabis Attitudes Media plays a pivotal role in shaping public perception, and the portrayal of medical cannabis is no exception.
Expert insights. Personalized for you.
52 
Let's personalize your content